Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026)

Neumora Therapeutics' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $88.0 million, a 345.21% increase from a year earlier, with the FY2025 full-year figure at $77.1 million, up 256.84% from the prior year.
• Cash from Financing Activities slipped to $10.9 million in Q1 2026 per NMRA's latest filing, from $58.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $232.0 million in Q3 2023 and bottomed at -$481000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $2.7 million (2024), against an average of $28.3 million.
• Across the five-year window, Cash from Financing Activities surged 3337.63% in 2024 and sank 108.88% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $26.8 million in 2022, then sank by 101.79% to -$481000.0 in 2023, then jumped by 3337.63% to $15.6 million in 2024, then soared by 277.37% to $58.8 million in 2025, then plunged by 81.5% to $10.9 million in 2026.
• Per Business Quant, the three latest NMRA Cash from Financing Activities figures stand at $10.9 million (Q1 2026), $58.8 million (Q4 2025), and -$136000.0 (Q3 2025).